|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的Ⅱ期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11)显示文摘背景与目的一项比较艾日布林联合吉西他滨(eribulin plus gemcitabine,EG)或紫杉醇联合吉西他滨(paclitaxel plus gemcitabine,PG)作为转移性乳腺癌(metastatic breast cancer,MBC)患者一线化疗方案的II期临床试验发现,EG方案的神经毒性较低,但疗效与PG方案相似。在本研究中,我们分析了该临床实验中的癌症患者生命质量测评量表–紫杉烷(functional assessment of cancer therapy-taxane,FACT-Taxane)问卷评分以确定他们的生活质量(quality of life,QoL)。方法使用韩国版的FACT-Taxane问卷评估QoL。在评估基线之后,前12个疗程中每2个疗程评估1次QoL,之后每3个疗程评估1次QoL。使用线性混合模型评估EG组和PG组QoL的差异。结果在118例入组患者中,117例在基线时回复了FACT-Taxane问卷,PG组中有1例患者没有回复。EG组和PG组之间的基线QoL评分没有差异。在治疗期间,除了第11个疗程外,在第2–13个化疗疗程后,PG组紫杉烷亚量表评分显著高于EG组(均P<0.05)。神经病变特异性分析显示PG组患者的神经病症状比EG组患者更早出现且更严重(P<0.001)。结论在我们的QoL分析中,与PG方案相比,EG方案延迟并减少神经病变的发生。因此,艾日布林是MBC一线化疗药物紫杉醇的合理替代品。 | Ji‑Yeon Kim Seri Park Seock‑Ah Im Sung‑Bae Kim Joohyuk Sohn Keun Seok Lee Yee Soo Chae Ki Hyeong Lee Jee Hyun Kim Young‑Hyuck Im Tae‑Yong Kim Kyung‑Hun Lee Jin‑Hee Ahn Gun Min Kim In Hae Park Soo Jung Lee Hye Sook Han Se Hyun Kim Kyung Hae Jung Yeon Hee Park Korean Cancer Study Group | 2019 | 癌症2019，38，8： | 2 |
| 2 | Gastrointestinal bleeding in adult patients with Henoch–Sch?nlein purpura显示文摘 | Eon Nam Gun Kim Jong Kang Churl Im Seong Jeon Chang-Min Cho Ji Jeong Ji Park Yun Jang Young Kang | 2014 | Endoscopy2014，，11： | 1 |
| 3 | Quality of life outcomes including neuropathy-associated scale from a phase II,multicenter,randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer:Korean Cancer Study Group Trial(KCSG BR13-11)显示文摘Background: A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen. In the present study, we analyzed functional assessment of cancer therapy-taxane (FACT-Taxane) questionnaires from patients in this clinical trial to determine their quality of life (QoL). Methods: QoL was assessed using the Korean version of the FACT-Taxane questionnaires. After baseline assessment, QoL was assessed every 2 cycles for 12 cycles and every 3 cycles thereafter. The linear mixed model was used to evaluate the difference in QoL between the EG and PG arms. Results: Of the 118 enrolled patients, 117 responded to the FACT-Taxane questionnaires at baseline, 1 in the PG arm did not. Baseline QoL scores were not different between the EG and PG arms. During treatment, taxane subscale scores were significantly higher in the PG arm than in the EG arm after 2-13 cycles of chemotherapy (all P < 0.05), except for the 11th cycle. Neuropathy-specific analysis showed that patients in the PG arm had earlier and more severe neuropathic symptoms than those in the EG arm (P < 0.001). Conclusions: In our QoL analysis, the EG regimen delayed and decreased neuropathy as compared with the PG regimen. Therefore, eribulin would be a reasonable substitute for paclitaxel as first-line chemotherapy for MBC. | Ji-Yeon Kim Seri Park Seock-Ah Im Sung-Bae Kim Joohyuk Sohn Keun Seok Lee Yee Soo Chae Ki Hyeong Lee Jee Hyun Kim Young-Hyuck Im Tae-Yong Kim Kyung-Hun Lee Jin-Hee Ahn Gun Min Kim In Hae Park Soo Jung Lee Hye Sook Han Se Hyun Kim Kyung Hae Jung Yeon Hee Park Korean Cancer Study Group | 2019 | Cancer Communications2019，39，1： | 1 |
| 4 | Repair of cartilage defect in the rabbit with cultured mesenchymal stem cells from bone marrow 显示文摘 | Gun IM Kim DY Shin JH | 2001 | J Bone Surg2001，83，2： | 1 |
| 5 | Lumbar Posterolateral Fusion Using Heparin‐Conjugated Fibrin for Sustained Delivery of Bone Morphogenic Protein‐2 in a Rabbit Model显示文摘 | Ki Hyoung Koo Do Hyun Yeo Jung Min Ahn Byung‐Soo Kim Chang‐Sung Kim Gun‐Il Im | 2012 | Artificial Organs2012，，7： | 1 |
| 6 | 禁忌用药对Dravet综合征认知结局的影响及初次非高热性痫性发作年龄对SCN1A相关痫性发作表型的临床预测作用显示文摘SCN1A致病性变异可引起不同严重程度的疾病表型,而这在疾病初期可能难以辨别。研究组致力于探究有助于预测痫性发作分别向Dravet综合征演变和预测Dravet综合征认知结局的临床特征,分析了禁忌用药对认知减退的可能调节作用。评估由164例SCN1A相关痫性发作的荷兰患者组成的队列研究。临床数据通过医疗记录和半结构式电话回访获得。认知功能由一名儿童神经科医师、一名神经心理医师和一名临床基因学家测评分类。通过单因素和多因素回归分析多项临床变量(包括在病程前5年禁忌用药的持续时间)发现,起病前5年内更长时间的禁忌用药与纳入研究时更差的认知结局显著相关,同时与Dravet综合征患者第一个5年病程后更低的内插智商值和发育智商值有关。多因素线性回归分析提示,禁忌用药是认知结局的一个重要预测因素。此外,初次发现发育迟缓的年龄和初次非高热性痫性发作年龄也是其重要的预测因素。而在完整的队列中,初次非高热性痫性发作年龄是痫性发作向Dravet综合征演变最准确的预测因素。比研究数据提示病程前5年内更长时间的禁忌用药对Dravet综合征患者的认知结局有负面影响。早期诊断对于避免使用这些禁忌药物极为重要。研究还发现初次非高热性痫性发作年龄是痫性发作向Dravet综合征演变以及Dravet综合征疾病严重程度的重要预测因素,这些都可为SCN1A相关痫性发作年幼患者的父母提供建议。 | de Lange IM Gunning B Sonsma ACM 覃英杰(译) 慕洁(审) 熊维希(审) | 2019 | 癫痫杂志2019，0，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员